Vice Chair for Veterans Affairs, Department of Medicine
Patrick J. Strollo, Jr., M.D. is a Professor of Medicine and Clinical and Translational Science in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh. He is the Director of the UPMC Sleep Medicine Center and Co-Director of the Sleep Medicine Institute at the University of Pittsburgh.
He received his MD from the Uniformed Services University of the Health Sciences in 1981 and trained in Internal Medicine and Pulmonary / Critical Care at Wilford Hall USAF Medical Center in San Antonio, Texas.
He is currently a member of the Executive Committee of the Board of Directors of the American Academy of Sleep Medicine and the Executive Committee of the American Thoracic Society Sleep and Respiratory Neurobiology Assembly. He is a member of the American Board of Internal Medicine Pulmonary Disease Board of Directors. He is a member of the National Football League’s Cardiovascular Health Committee. He has been recognized by Best Doctors® in Pulmonary, Critical Care and Sleep Medicine and Castle Connolly’s Top Doctors in Pulmonary Disease.
Dr Strollo’s clinical work focuses on the diagnosis, treatment and long term management of Sleep Apnea and Respiratory Care of patients with neuromuscular disease.
His projects have examined the utility of portable monitoring for the diagnosis of sleep apnea, treatment of sleep apnea with new modalities of positive pressure and the impact of sleep apnea on cardiovascular risk.
His research has been funded by the Respironics, ResMed, National Football League, Department of Defense, National Heart Lung and Blood Institute and Pennsylvania Tobacco Settlement.
Animal and human data suggest that obstructive sleep apnea (OSA) leads to hypertension as a result of intermittent sympathetic overflow related to apnea / hypopnea events. This subsequently leads to endothelial dysfunction and ultimately atherosclerosis (ASCAD). Intermittent hypoxia may contribute to the elaboration of free radicals / inflammatory mediators. OSA may affect lipid metabolism resulting in atherogenic profiles further contributing plaque formation.
After adjusting for the likely confounding variables (i.e. age, gender, race, statin use, smoking, abnormal blood pressure and BMI), moderate to severe Sleep Apnea (AHI > 25) conferred a 3.6 fold risk of having an atherogenic lipid profile (LDL subclass B). Proceedings of the American Thoracic Society 2006 3:A871.
Substantial numbers of patients with severe sleep apnea (AHI > 30) do not report subjective sleepiness (Epworth Sleepiness Score < 10) and have been labeled as the non-sleepy sleep apnea phenotype (right lower quadrant). These patients are frequently difficult to treat and may have lower cardiovascular risk than the sleepy sleep apnea phenotype (right upper quadrant).
Strollo PJ, Rogers RM. Obstructive Sleep Apnea. N Engl J Med 1996 334:99-104
Collop, NA, Shepard JW Jr., Strollo, PJ Executive Summary on the Systematic Review and Practice Parameters for Portable Monitoring in the Investigation of Suspected Sleep Apnea in Adults. Am J Respir Crit Care Med 2004 169:1160-1163
Ballard RD, Gay PC, Strollo PJ. Interventions to Improve Compliance in Sleep Apnea Patients Previously Non-Compliant with Continuous Positive Airway Pressure. J Clin Sleep Med 2007 Vol. 3, No. 7
Watch an interview with Dr. Strollo as he discusses a new free Sleep Program coming to UPMC Shadyside.
Dr. Strollo was named one of the "Top Doctors" in Pittsburgh Magazine, 2007.
He was also quoted in the following web articles: